Stock Market & Financial News
Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript
Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript
NAGE Betting on the Backbone: REX Files for AI Chipmaking ETF
Investor demand for AI chip manufacturers has surged this year. The industry is expected to reach revenues of $1.3 trillion in 2026, according to Yahoo Finance, driven by a global AI infrastructure buildout and a bottleneck for AI semiconductors and hardware.
REX Polymarket Bitcoin Markets Show Manipulation Evidence, Stanford Research Reveals
Researchers at Stanford University have published findings suggesting that Bitcoin prediction markets on Polymarket, a leading decentralized betting platform, may have been subject to coordinated manipulation.
Can Valero Energy (VLO) Run Higher on Rising Earnings Estimates?
Valero Energy (VLO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
VLO 
Can Werner (WERN) Run Higher on Rising Earnings Estimates?
Werner Enterprises (WERN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
WERN 
Booking, Alphabet, and 7 Other Stocks to Buy Ahead of Earnings
Booking Holdings, Alphabet, and six other companies have underperformed their sectors despite improving earnings expectations, setting up potential upside during second-quarter earnings season.
BKNG 
Forget Chasing Yield: This Is the Best Dividend ETF if You Actually Reinvest
Chasing yield is the most expensive habit in dividend investing, and the iShares Core Dividend Growth ETF (NYSEARCA:DGRO) exists precisely because a lot of investors keep doing it anyway.
DGRO 
Historic IBM stock crash sets up unique options strategy
IBM shares fell just over $73 to ~$217 — a jaw-dropping 25% single-day decapitation.
IBM 
SK Hynix: Cheap With Robust AI Monetization Prospects, Lockup/Oversupply Risks Loom
SKHY's successful US debut is powered by surging DRAM/HBM prices and aggressive hyperscaler capex trends, with it contributing to the outsized, multi-year top-line growth and margin expansion prospects. The FQ2'26 earnings call may also benefit from the retooling of some of the HBM3E capacity for DRAM production, given the latter's soaring prices/richer profit margins. Multi-year LTAs, robust cash flow, rich balance sheet, and successful US debut with $26.5B raised, support SKHY's aggressive capacity expansion cadence.
HBM 
Paradex integrates RFQ engine, executes $23M XRP options block
Paradex's RFQ integration may boost DeFi's institutional appeal, potentially enhancing XRP liquidity and influencing future market dynamics. Paradex integrates RFQ engine, executes $23M XRP options block.
PayPal stock is skyrocketing after Stripe and a private equity firm reportedly made a buyout offer
Shares in PayPal Holdings (Nasdaq: PYPL) are skyrocketing in premarket trading this morning after a report that the legacy digital payments platform has received a joint buyout offer from one of today's most successful fintech companies and a major private equity firm. Here's what you need to know.
PYPL 
XRP Officially Enters DTCC's Collateral Framework as Institutional Recognition Deepens
XRP has secured a DTCC classification for clearing and haircut framework.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical Services, Inc. WST is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff impacts, destocking in generics and execution challenges at constrained European facilities are concerning.
WST 
Visa Strengthens Value-Added Services With AI Assistant for Banks
Visa launches AI Financial Assistant to bring secure, conversational financial guidance into banking apps, expanding its value-added services strategy.
V 
Why ASML's AI Monopoly Is Still Getting Stronger
ASML NASDAQ: ASML holds a monopoly on foundational AI technology, making it the most structurally sound tech investment you can own. Its Extreme Ultraviolet (EUV) lithography machines are the only ones capable of printing AI-capable circuitry, and they are in high demand.
ASML 
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
RHHBY 
Will Apple (AAPL) Beat Estimates Again in Its Next Earnings Report?
Apple (AAPL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AAPL 
Why Chevron (CVX) is Poised to Beat Earnings Estimates Again
Chevron (CVX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CVX 
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BMY 
Will AT&T (T) Beat Estimates Again in Its Next Earnings Report?
AT&T (T) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
T 
Will UnitedHealth (UNH) Beat Estimates Again in Its Next Earnings Report?
UnitedHealth (UNH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
UNH 
Will Atmus Filtration (ATMU) Beat Estimates Again in Its Next Earnings Report?
Atmus Filtration (ATMU) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ATMU 
Will Cummins (CMI) Beat Estimates Again in Its Next Earnings Report?
Cummins (CMI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CMI 
Why Ally Financial (ALLY) is Poised to Beat Earnings Estimates Again
Ally Financial (ALLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ALLY 
Will Avantor (AVTR) Beat Estimates Again in Its Next Earnings Report?
Avantor (AVTR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AVTR 
Why Corpay (CPAY) is Poised to Beat Earnings Estimates Again
Corpay (CPAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CPAY 
Will Monster Beverage (MNST) Beat Estimates Again in Its Next Earnings Report?
Monster Beverage (MNST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MNST 
Will Entegris (ENTG) Beat Estimates Again in Its Next Earnings Report?
Entegris (ENTG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ENTG 
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ELAN 
Will Esco Technologies (ESE) Beat Estimates Again in Its Next Earnings Report?
Esco Technologies (ESE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ESE 
